Hologic Navigates Breast Health Slump: Is the Growth Thesis Intact?

Key Takeaways HOLX's Breast Health segment fell 6.2% in Q2, continuing a decline led by weaker capital equipment sales. Despite softness, Hologic's service revenues rose 12%, driven by a large global gantry install base. HOLX eyes a growth rebound in Q4 and plans a 2026 launch of its FDA-cleared Envision mammography platform.Women’s health medical device maker, Hologic (HOLX) , is struggling with continued softness in its core Breast Health segment. Sales fell 6.2% in the fiscal 2025 second quarter due to ...